Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Blood pressure pill showdown pulled before it began

NCT ID NCT02483936

Disease control Sponsor: EMS Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled This study
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study aimed to compare two different combination pills for controlling high blood pressure: one with olmesartan and chlorthalidone, and another with olmesartan and hydrochlorothiazide (Benicar HCT). The trial was planned for people with uncontrolled hypertension but was withdrawn before any participants were enrolled. No results are available.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
olmesartan medoxomil + chlorthalidone
What this could lead to
If successful, this could offer a new fixed-dose combination pill for controlling high blood pressure.
What could go wrong
The trial was withdrawn before enrolling any participants, so no results are available. It is unclear if the combination would have been safer or more effective than existing options.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Phase 3

Large-scale testing in a bigger group. Usually the last step before a treatment can be approved.

Lead sponsor

A company

The lead sponsor is a pharmaceutical, biotech, or medical-device company.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 to 65 years

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Signed Consent of the patient; * Participants with decompensated essential hypertension, classified into stage 1 (with high or very high cardiovascular risk), stage 2 or stage 3 according to the Brazilian Society of Cardiology (2010), who are being treated with monotherapy. Exclusion Criteria: * Patients with any clinically significant disease that in the investigator opinion can not participate in the study; * Secondary hypertension diagnosis or blood pressure above 190x100 mmHg in the screening/randomization visit; * Morbid obesity or immunocompromised patients; * Participants with greater than 10 mmHg difference in the measurements of systolic or diastolic blood pressure between the two arms; * Participants who do not have the two upper limbs; * Participants with important electrocardiographic changes; * Creatinine clearance - less than 60 mL / min; * History of hypertensive emergencies and cardiovascular and / or moderate to severe cerebrovascular events in the past 6 months; * Microalbuminuria urine sample greater than 30 mg/g; * Patients with history of hypersensitivity to any of the formula compounds; * Pregnancy or risk of pregnancy and lactation patients; * Participation in clinical trial in the year prior to this study;

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Arterial hypertension are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

essential hypertension hypertensive disorder

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Arterial hypertension

More trials for these conditions

Other studies related to the condition(s) this trial covers.